Close Menu

SARS-CoV-2 (COVID-19) eCase Study Series

About The Series  
This three part GenomeWeb eCase study series, sponsored by LGC SeraCare Life Sciences, addresses SARS-CoV-2 quality solutions, verification panels and reference materials. 


PART 1 | Presenter: Jeff SoRelle, M.D.Clinical Pathology Resident, University of Texas Southwestern Medical Center

Experience with SARS-CoV-2 (COVID-19) Assay Validation

Register Here

In this 20 minute eCase Study you will hear first-hand how Dr. Jeff SoRelle and team, of the University of Texas Southwestern Medical Center, developed and validated a COVID-19 RT PCR assay. Jeff shares his decision to bring this development in house, how he chose reference materials, and how he managed to scale up and provide rapid turnaround.

PART 2 | Presenter: Joel Lefferts, PhD, HCLD, DABCCAssistant Director of Clinical Genomics and Advanced Technology Lab and Assistant Professor of Pathology and Laboratory Medicine Dartmouth-Hitchcock Medical Center and Geisel School of Medicine at Dartmouth

Rapid Implementation of SARS-CoV-2 Testing

Register Here

Hear how Dr. Joel Lefferts and his team at the Dartmouth-Hitchcock Medical Center were able to rapidly increase, through automation, their SARS-VoV-2 assay on the Abbott M2000. Joel will provide practical experiences and challenges faced when developing, validating and going live with a SARS CoV-2 assay to facilitate patient testing.

PART 3 | Presenter: Russell Garlick, PhD, Chief Scientific Officer, LGC SeraCare Life Sciences

Expert Advice Establishing a SARS-CoV-2 Assay for COVID-19

Register Here

Learn how Accuplex™ SARS-CoV-2 Reference Materials are meeting the immediate need, and the critical role they play in validating the performance of Coronavirus Assay. The focus is on the technology, the importance of early detection and helping every lab accelerate go live launch.

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.